Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Diabetic Patients With Aortocoronary Bypass (Executive)

This study has been completed.
Eli Lilly and Company
Information provided by (Responsible Party):
Martin Haluzik, Charles University, Czech Republic Identifier:
First received: June 10, 2011
Last updated: July 27, 2015
Last verified: July 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2014
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)